Effects of chronic, oral amiodarone on left ventricular pressure, electrocardiograms, and action potentials from myocardium in vivo and from purkinje fibers in vitro

Veterinary Therapeutics

Volumn 2, Issue 4, 2001, Pages 325-333

  Bicer, Sabahattin ^a   Nakayama, Hitomi ^a   Nakayama, Tomohiro ^a   Strauch, Stephen M ^a   Hamlin, Robert L ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE;

ACTION POTENTIAL; ANIMAL; ANIMAL DISEASE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOG; DRUG ADMINISTRATION; DRUG EFFECT; ELECTROCARDIOGRAPHY; FEMALE; HEART MUSCLE; HEART RATE; MALE; PHYSIOLOGY; PURKINJE FIBER;

ACTION POTENTIALS; AMIODARONE; ANIMALS; DOGS; DRUG ADMINISTRATION SCHEDULE; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; MALE; MYOCARDIUM; PURKINJE FIBERS;

EID: 0344269935     PISSN: 15283593     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Singh BN, Vaughan Williams EM: The effect of amiodarone, a new antianginal drug, on cardiac muscle. Br J Pharmacol 39:657-667, 1970.
2. Yabek SM, Kato R, Singh BN: Effects of amiodarone and its metabolite, desethylamiodarone, on the electrophysiologic properties of isolated cardiac muscle. J Cardiovasc Pharmacol 8:197-207, 1986.
3. Yabek SM, Kato R, Singh BN: Acute effects of amiodarone on the electrophysiologic properties of isolated neonatal and adult cardiac fibers. J Am Coll Cardiol 5:1109-1115, 1985.
4. Drouin E, Lande G, Charpentier F: Amiodarone reduces transmural heterogeneity of repolarization in the human heart. J Am Coll Cardiol 32:1063-1067, 1998.
5. Rosenbaum MB, Chiale PA, Halpern MS, et al: Clinical efficacy of amiodarone as an antiarrhythmic agent. Am J Cardiol 38:934-944, 1976.
6. Siddoway LA, McAllister B, Wilkinson GR, et al: Amiodarone dosing: A proposal based on its pharmacokinetics. Am Heart J 106:951-956, 1983.
7. Calvert AC, Meurs KM: Cardiopulmonary diseases: Doberman pinscher occult cardiomyopathy: Ventricular tachyarrhythmia. In: Kirk RW, ed. Current Veterinary Therapy. Philadelphia, PA: WB Saunders; 2000:756-760.
8. Bicer S, Schwartz DS, Nakayama T, Hamlin RL: Hemodynamic and electrocardiographic effects of graded doses of amiodarone in healthy dogs anesthetized with morphine/alpha chloralose. J Vet Intern Med 14:90-95, 2000.
9. Singh BN, Jewitt DE, Downey JM: Effects of amiodarone and L8040, novel antianginal and antiarrhythmic drugs, on cardiac and coronary hemodynamics and on cardiac intracellular potentials. Clin Exp Pharmacol Physiol 3:427-442, 1976.
10. Singh BN: Amiodarone: Historical development and pharmacologic profile. Am Heart J 106:788-797, 1983.
11. Haffajee CI, Love JC, Alpert JS: Efficacy and safety of long-term amiodarone in treatment of cardiac arrhythmias: Dosage experience. Am Heart J 106:935-943, 1983.
12. Aomine M: Acute effects of amiodarone on action potentials of isolated canine Purkinje fibers: Comparison with tetradoxin effects. Gen Pharmacol 19:601-607, 1988.
13. Kodama I, Kamiya K, Honjo H, Toyama J: Acute and chronic effects of amiodarone on mammalian ventricular cells. Jpn Heart J 37:719-730, 1996.
14. Winslow E, Campbell JK, Barron E: Effects of amiodarone on cardiac electrophysiology and inducibility of arrhythmias in chronically infarcted dogs: Late arrhythmias, haemodynamics, and sympatholytic actions. J Cardiovasc Pharmacol 16:896-904, 1990.
15. Levine JH, Moore EN, Kadish AH, et al: Mechanisms of depressed conduction from long-term amiodarone therapy in canine myocardium. Circulation 78:684-691, 1988.
16. Ikeda N, Nademanee K, Kannan R, Singh BN: Electrophysiologic effects of amiodarone: Experimental and clinical observation relative to serum and tissue concentrations. Am Heart J 108:890-898, 1984.
17. Gallagher JD, Bianchi J, Gessman LJ: A comparison of the electrophysiologic effects of acute and chronic amiodarone administration on canine Purkinje fibers. J Cardiovasc Pharmacol 13:723-729, 1989.
18. Merot J, Charpentier F, Poirier JM, et al: Effects of chronic treatment by amiodarone on transmural heterogeneity of canine ventricular repolarization in vivo: Interactions with acute sotalol. Cardiovasc Res 44: 303-314, 1999.
19. Haffajee CI, Love JC, Canada AT, et al: Clinical pharmacokinetics and efficacy of amiodarone for refractory tachyarrhythmias. Circulation 67:1347-1355, 1983.
20. Sicouri S, Moro S, Litovsky S, et al: Chronic amiodarone reduces transmural dispersion of repolarization in the canine heart. J Cardiovasc Electrophysiol 8:1269-1279, 1997.
21. Hohnloser SH: Proarrhythmia with class III antiarrhythmic drugs: Types, risks, and management. Am J Cardiol 80(8A):82G-89G, 1997.
22. Cui G, Sen L, Sager P, Uppal P, Singh BN: Effects of amiodarone, sematilide, and sotalol on QT dispersion. Am J Cardiol 74:896-900, 1994.
23. Hii JTY, Wyse G, Gillis AM, Duff HJ, Solylo MA, Mitchell LB: Precordial QT interval dispersion as a marker of torsade de pointes, disparate effects of class Ia antiarrhythmic drugs and amiodarone. Circulation 86:1376-1382, 1992.